focus -WSS

focus

author：hotspot 2025-09-27 10:02:53 - browse：2775

Becton Dickinson plans to pay $4.2 billion for Edwards Lifesciences’ critical care business, which sells technology that monitors the heart conditions of critically ill patients.

Edwards had told investors in December 2023 that it planned to spin off the business in order to focus more sharply on addressing structural defects in the heart. BD, meanwhile, wants to increase its monitoring presence in hospitals. In a statement announcing the acquisition, the company touted the “advanced AI algorithms” used in Edwards’ monitors.

BD CEO Tom Polen said in a statement that the acquisition will bolster BD’s portfolio of “AI-enabled clinical decision tools” and digital health products in general.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

WSS

Adopting new red light myopia treatments may be short

Gene therapy for Afghan refugees’ infant will be fully covered

New report analyzes digital physical therapy solutions' effectiveness

Cheap, fast test for Zika and dengue could cost just $1

Bernie brings in new pharma CEOs to talk drug prices

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Apple is now the first public company to be valued at $3 trillion

'Essentially witchcraft:' A former naturopath takes on the field

Alkermes shareholders re

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

State Dept. review finds Biden bears some blame for Afghanistan failures

New report analyzes digital physical therapy solutions' effectiveness

New air purifier tech could be key to improving indoor air quality

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

explore

Cheap, fast test for Zika and dengue could cost just $1

The system is set up to fail children with medical complexity

How faith leaders like me can help address America's obesity epidemic

5 takeaways from STAT's examination of Zynex Medical

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Pharma companies must ensure equitable access to obesity drugs

knowledge

Wikipedia

hotspot

focus